| Benign prostatic hyperplasia | Causes | Unclear | 1.00 | infobox |
| Benign prostatic hyperplasia | Complications | Urinary tract infections, bladder stones, kidney failure | 1.00 | infobox |
| Benign prostatic hyperplasia | Diagnostic method | Based on symptoms and examination after ruling out other possible causes | 1.00 | infobox |
| Benign prostatic hyperplasia | Differential diagnosis | Heart failure, diabetes, prostate cancer | 1.00 | infobox |
| Benign prostatic hyperplasia | Frequency | 94 million men affected globally (2019) | 1.00 | infobox |
| Benign prostatic hyperplasia | Medication | Alpha blockers such as terazosin, 5α-reductase inhibitors such as finasteride | 1.00 | infobox |
| Benign prostatic hyperplasia | Other names | Benign enlargement of the prostate (BEP, BPE), adenofibromyomatous hyperplasia, benign prostatic hypertrophy, benign prostatic obstruction | 1.00 | infobox |
| Benign prostatic hyperplasia | Risk factors | Family history, obesity, type 2 diabetes, not enough exercise, erectile dysfunction | 1.00 | infobox |
| Benign prostatic hyperplasia | Specialty | Urology | 1.00 | infobox |
| Benign prostatic hyperplasia | Symptoms | Frequent urination, trouble starting to urinate, weak stream, inability to urinate, loss of bladder control | 1.00 | infobox |
| Benign prostatic hyperplasia | Treatment | Lifestyle changes, medications, several procedures, surgery | 1.00 | infobox |
| Benign prostatic hyperplasia | Usual onset | Age over 40 | 1.00 | infobox |
| Benign prostatic hyperplasia | is a | consequence of fibrosis and weakening of the muscular tissue in the prostate | 0.90 | text |
